Every 10-Q that Disc Medicine, Inc. (IRON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRON filings page.
Disc Medicine, Inc. is a clinical-stage biopharma focused on serious hematologic diseases. For Q2 2026 it reported a net loss of about $59.5M, versus $55.2M a year earlier; first-half net loss was about $123.0M, driven by higher research and development spending and increased selling, general and administrative costs as headcount and commercialization planning expanded.
Cash, cash equivalents and marketable securities totaled $717.7 million as of June 30, 2026, and management expects this to fund planned operating expenses, capital expenditures and debt service into 2029. Bitopertin, for erythropoietic porphyrias, received an FDA complete response letter, but the fully enrolled Phase 3 APOLLO trial (n=183) could, if successful, support a traditional approval, with topline data expected in Q4 2026 and a potential FDA decision by mid‑2027. Selcodebart (DISC‑0974) and DISC‑3405 continued through multiple Phase 2 and Phase 1b studies targeting anemia and iron‑related disorders.
Disc Medicine reported a larger quarterly loss as it accelerates clinical development. For the three months ended March 31, 2026, net loss was $63.5 million (vs. $34.1 million), or $1.65 per share. Research and development rose to $45.9 million, driven by the DISC‑3405 program, milestones and higher headcount, while selling, general and administrative expenses increased to $23.6 million as the company builds commercial capabilities.
Disc ended the quarter with $730.2 million in cash, cash equivalents and marketable securities and expects this to fund operations and debt obligations into 2029. The pipeline includes Phase 3 bitopertin in erythropoietic porphyrias, DISC‑0974 in anemia of myelofibrosis and inflammatory bowel disease, and DISC‑3405 in polycythemia vera and sickle cell disease.
Disc Medicine (IRON) reported Q3 2025 results showing continued investment in its hematology pipeline. Net loss was $62.3 million for the quarter and $151.7 million year-to-date, driven by research and development of bitopertin, DISC-0974, and DISC-3405.
R&D expense was $50.3 million and SG&A was $17.4 million in Q3. Liquidity remained strong with cash, cash equivalents and marketable securities of $615.9 million as of September 30, 2025, supported by a $243.4 million January underwritten offering, $9.8 million from ATM sales in Q3, and a $30.0 million term loan. The company recorded milestone payments of $10.0 million to Roche and $10.0 million to Mabwell tied to clinical progress.
Subsequent to quarter‑end, an underwritten offering on October 20, 2025 is expected to add net proceeds of approximately $210.9 million. Shares outstanding were 37,750,162 as of October 31, 2025.
Disc Medicine (NASDAQ: IRON) filed its Q2-25 Form 10-Q. The clinical-stage biotech remains pre-revenue and focuses on hematologic programs bitopertin, DISC-0974 and DISC-3405.
- Cash, cash equivalents and marketable securities rose to $650.0 million (Dec-24: $489.9 m), driven by a January 2025 equity raise that netted $243 m.
- Q2 operating loss widened to $61.4 m (Q2-24: $30.9 m) as R&D expense nearly doubled to $46.3 m; SG&A increased to $15.1 m.
- Net loss was $55.3 m, or –$1.58/sh; 6-month loss was $89.3 m.
- Term-loan debt totals $30 m (net carrying value $28.7 m) under a Hercules facility maturing 2029; minimum-cash covenant waived while market cap ≥$1 bn.
- Milestone outflows: $10 m to Roche (Phase 3 start) and $3 m to AbbVie (Phase 2 start).
- Runway: management states funds are sufficient for at least 12 months and to support planned NDA submission (Oct-25) seeking accelerated approval of bitopertin for EPP/XLP.
Key pipeline events: APOLLO Phase 3 trial of bitopertin initiated May-25; Phase 2 readouts for DISC-0974 (MF & CKD anemia) expected 2H-25. The company also completed an asset acquisition (clinic-ready MDS program) with up to $50 m contingent payments.